Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pre|CISION dual payload compounds
- Development stage
- Preclinical
- Lead developer
- Avacta
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides
01
Overview
Avacta Therapeutics' pre|CISION dual payload compounds are a novel class of peptide-drug conjugates (PDCs) designed to deliver two distinct therapeutic payloads specifically to the tumor microenvironment. The technology utilizes a proprietary peptidic substrate (D-Ala-L-Pro) that is selectively cleaved by Fibroblast Activation Protein alpha (FAP), a protease highly overexpressed in the stroma of over 90% of solid tumors. By engineering two complementary payloads—such as the topoisomerase I inhibitor exatecan combined with a PARP inhibitor, ATR inhibitor, or MMAE—into a single molecule, these compounds aim to maximize therapeutic efficacy and overcome drug resistance while minimizing systemic toxicity. The lead dual-payload program is identified as AVA6207, and the platform is currently in preclinical development for the treatment of various solid tumors.
- Brand names
- pre|CISION
- Other names
- FAP-activated dual payload PDCspre|CISION Peptide-Drug Conjugates
02
Targets
FAP (Fibroblast activation protein alpha)TOP1 (DNA Topoisomerase I)PARP1 (Poly (adp-ribose) polymerase 1)ATR (ATR serine/threonine kinase)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on pre|CISION dual payload compounds.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pre|CISION dual payload compounds.